Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of Lu AG06479 in Healthy Men
NCT04473651Phase 1Terminated
- Sponsor
- Lundbeck
- Start
- Jul 2020
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of lu ag06479 in schizophrenia, psychosis and schizoaffective disorder (3 arms), sponsored by Lundbeck. Primary endpoint: Treatment Emergent Adverse Events at Day 9. Started Jul 2020; status: terminated.
02
Drugs
lu ag06479
03
Conditions
schizophreniapsychosisschizoaffective disorder
Beyond the preview
Go deeper on NCT04473651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04473651.